GoodRx Holdings Inc. (NASDAQ:GDRX) reported fourth-quarter revenue of $198.6 million, up slightly by 1% year over year, missing the management guidance of around $200 million and consensus of $199.75 million.
Fiscal year sales of $792.3 million came in below the guidance of around $794 million.
The company reported adjusted EPS of 9 cents, up from 8 cents a year ago, missing the consensus of 10 cents.
Q4 prescription transactions revenue increased 0.8% to $144.9 million. 2024 prescription transactions revenue increased 5% to $577.5 million, driven by an organic 7% increase in Monthly Active Consumers, including the expansion of an integrated savings program.
Also Read: How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
GoodRx exited the fourth quarter of 2024 with over 7 million prescription-related consumers using GoodRx across prescription transactions and subscription offerings. Monthly active consumers were 6.6 million, with subscription plans of 684k.
The 2024 subscription revenue decreased by 8% to $86.5 million, primarily driven by a decrease in subscription plans due to the sunset of the partnership subscription program, Kroger Savings Club. In Q4, subscription revenue fell 10.7% to $20.68 million.
Q4 Pharma manufacturer solutions revenue jumped from $24.4 million to $28.1 million. 2024 Pharma manufacturer solutions revenue increased 26% to $107.2 million, primarily driven by organic growth as the company expands market penetration with pharma manufacturers and other customers.
Adjusted EBITDA reached $67.08 million in Q4 and $260.2 million in 2024.
Guidance: The prescription savings platform expects a fiscal year 2025 revenue outlook of $810 million—$840 million, up 2%—6% versus the consensus of $825.57 million, with adjusted EBITDA of $270 million—$286 million.
GoodRx forecasts first-quarter 2025 revenue of $201 million—$205 million, up 2%-4%, versus consensus of $202.53 million, with an adjusted EBITDA margin of about 33%.
Price Action: GDRX stock is up 4.6% at $5.12 at the last check Thursday.
Read Next:
Photo: Shutterstock
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。